Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE MSA: Inosine 5'-Monophosphate in Multiple System Atrophy
NCT03403309Phase 2Completed
- Sponsor
- Yonsei University
- Start
- May 2018
- Primary completion
- Jun 2019
- Modality
- Modified DNA Aptamers, Spiegelmers, Modified DNA Oligonucleotides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing Inosine 5'-monophosphate arm with Placebo arm (2 arms). Primary endpoints: Serum uric acid elevation, Safety and 1 more. Started May 2018; status: completed.
02
Drugs
inosine 5'-monophosphate
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT03403309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403309.